Fosdenopterin - Origin Biosciences
Alternative Names: ALXN-1101; BBP-870; cPMP; cPMP-cpd; Cyclic pyranopterin monophosphate (cPMP) replacement therapy - Origin Biosciences; Cyclic pyranopterin monophosphate - Origin Biosciences; Nulibry; ORGN 001Latest Information Update: 23 Apr 2024
At a glance
- Originator Orphatec Pharmaceuticals
- Developer BridgeBio Pharma; Origin Biosciences; Sentynl Therapeutics
- Class Alkadienes; Amines; Aza compounds; Ketones; Organophosphorus compounds; Pterins; Pyrans; Small molecules
- Mechanism of Action Molybdenum cofactor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Molybdenum cofactor deficiency
Most Recent Events
- 16 Apr 2024 Registered for Molybdenum cofactor deficiency (In children, In infants, In neonates) in United Kingdom (IV)
- 16 Apr 2024 BridgeBio Pharma intends to file NDA to Medicine and Healthcare products Regulatory Agency for Molybdenum cofactor deficiency (MoCD) Type A in the UK in the coming months
- 17 Oct 2022 Origin Biosciences completes a phase II/III trial in in Molybdenum cofactor deficiency (In children, In infants, In neonates) in the US, Israel, Norway, Spain, Turkey and the United Kingdom (NCT02629393) (EudraCT2013-002702-30)